Dr. Maki Yamamoto, MD

Dr. Yamamoto practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Yamamoto's NPI, 1336328194, was assigned on October 29, 2007. Dr. Yamamoto graduated from New York Medical College in 2004. Dr. Yamamoto holds California license A95898.

Dr. Yamamoto's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Yamamoto's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Yamamoto is also affiliated with Providence Mission Hospital. The medical group on file is UCI Health Physicians. Dmand AI also links Dr. Yamamoto to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yamamoto practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Yamamoto's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Yamamoto is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Yamamoto's licenses on file in 2 states: California and Florida.

Dmand AI lists cancerous skin growth removal and mastectomy among the conditions Dr. Yamamoto treats.

CMS data shows 574 Medicare services from Dr. Yamamoto across 11 procedure codes in 2024, for 322 Medicare patients. Medicare paid $44,657 for them.

CMS counts 322 Medicare patients who saw Dr. Yamamoto in 2024. The largest group is 65 to 74, with 136 patients. 74% of them have high cholesterol, and 73% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yamamoto's median patient age at 69, with 45% women.

In 2024, Dr. Yamamoto wrote 74 Medicare Part D claims for 63 patients. 99% of them were for generic drugs. CMS names the drug for 46 of them, across 2 drugs with 11 or more claims each, at $114 in total drug cost. In 2023, CMS named 53 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Yamamoto for performance year 2024, reported through an alternative payment model (APM). Dr. Yamamoto accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Yamamoto as offering telehealth. CMS counts 104 procedures of melanoma (skin cancer) excision by Dr. Yamamoto, more than 93% of the clinicians it reports for that procedure.

Hernia repair (minimally invasive): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 28 papers to Dr. Yamamoto, published from 2013 to 2025. 2021 was the busiest year, with 5. The most frequent topics are Melanoma, Skin Neoplasms and Sentinel Lymph Node Biopsy. Dr. Yamamoto has published most often in Am Surg. Dr. Yamamoto's most frequent co-authors are Jeffry T. Nahmias, MD, Areg Grigorian, MD and James G. Jakowatz, MD.

CMS Open Payments shows 25 general payments to Dr. Yamamoto from 4 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 79% of the total. Amgen Inc. paid the most, $18,797.

Dmand AI lists 1 award for Dr. Yamamoto.

Dr. Yamamoto graduated from New York Medical College in 2004. Dr. Yamamoto is a member of ACS.

Dr. Yamamoto is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.